Partial
Mostly Not Aligned
Patient Risk:
Medium
Summary
Several safety/monitoring statements are supported by the provided label text (notably LVEF monitoring and specific thrombocytopenia/peripheral neuropathy incidence ranges). However, most efficacy, trial design/outcome, labeled indication wording, and many adverse reaction rate claims rely on data that are not present in the provided label excerpts (Section 1 and Section 14 missing), limiting verification and accuracy confidence.
Category Scores
Accurate Statements
Monitoring for Kadcyla includes assessing left ventricular ejection fraction (LVEF) at regular intervals, e.g., every three months, during treatment.
Label 5.2: “Assess LVEF... and at regular intervals (e.g. every three months) during treatment...”
Kadcyla thrombocytopenia incidence is approximately in the ~29% (KATHERINE) to ~31% (EMILIA) range overall (study-specific).
Label 5.7: “In KATHERINE, the overall incidence of thrombocytopenia was 29%...” and “In EMILIA, the overall incidence... was 31%...”
Kadcyla peripheral neuropathy overall incidence in trials is reported as 21% (EMILIA) and 32% (KATHERINE overall), with Grade ≥3 peripheral neuropathy incidence of 2.2% (EMILIA) and 1.6% (KATHERINE).
Label 5.8: “In EMILIA... overall incidence... 21%... Incidence of Grade ≥ 3... 2.2%... In KATHERINE... overall incidence... 32%... Incidence of Grade ≥ 3... 1.6%.”
Kadcyla left ventricular dysfunction occurs at low frequencies in clinical trials (e.g., 0.4% in KATHERINE KADCYLA arm; 1.8% in EMILIA KADCYLA arm).
Label 5.2: “In KATHERINE, left ventricular dysfunction occurred in 0.4%... In EMILIA... occurred in 1.8%...”
Kadcyla should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to Grade ≤2.
Label 5.8: “KADCYLA should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to Grade ≤ 2.”
Unsupported Statements
Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate that targets HER2-positive breast cancer.
The provided label excerpts do not include a mechanism/description stating antibody-drug conjugate or targeting HER2-positive breast cancer (Section 1 not provided).
In the Phase III KATHERINE trial, Kadcyla reduced the risk of invasive disease recurrence or death by 50% compared with standard trastuzumab alone as adjuvant therapy.
Section 14 (Clinical Studies) text with the 50% risk reduction is not provided.
In the KATHERINE trial, patients received Kadcyla every 3 weeks for 14 cycles.
KATHERINE dosing regimen details are not present in the provided label excerpts.
In the KATHERINE trial, patients treated with Kadcyla had 88.3% event-free survival after a median 7.2 years of follow-up.
The provided excerpts do not include KATHERINE efficacy results with 88.3% and 7.2-year follow-up.
In the KATHERINE trial, patients treated with trastuzumab alone had 77.0% event-free survival after a median 7.2 years of follow-up.
The provided excerpts do not include KATHERINE efficacy results with 77.0% and 7.2-year follow-up.
FDA approval for Kadcyla in early breast cancer covers adults with HER2-positive early breast cancer at high risk of recurrence.
Section 1 (Indications and Usage) text is not provided; the specific approval/indication wording cannot be verified.
FDA approval for Kadcyla covers adults with residual invasive disease in the breast or lymph nodes after neoadjuvant taxane- and trastuzumab-based therapy.
Section 1 (Indications and Usage) text is not provided; the specific indication wording cannot be verified.
Kadcyla is not indicated for patients who achieve pathologic complete response (pCR) after neoadjuvant treatment.
No provided label text addresses pCR non-indication/eligibility criteria.
Kadcyla has a 4-year invasive disease-free survival of 88.3%.
No provided label excerpts include 4-year invasive disease-free survival results or the 88.3% value.
Kadcyla has a hazard ratio for recurrence of 0.50 versus trastuzumab.
No provided label excerpts include hazard ratio data.
Trastuzumab alone has a 4-year invasive disease-free survival of 77.0%.
No provided label excerpts include 4-year invasive disease-free survival results or the 77.0% value.
Kadcyla adds toxicity including liver enzyme elevation at a rate of 20%.
Label 5.1 describes hepatotoxicity and monitoring but provides no incidence/percent for “liver enzyme elevation at a rate of 20%.”
Kadcyla adds toxicity including peripheral neuropathy at a rate of 10%.
Label 5.8 provides peripheral neuropathy incidence values (e.g., 21% EMILIA; 32% KATHERINE), not 10%.
No overall survival benefit has been shown yet.
No provided label excerpts discuss overall survival benefit status.
Patients treated with Kadcyla have higher rates of fatigue (40%) than with trastuzumab alone.
No provided label excerpts provide fatigue incidence values (including 40%) or comparison to trastuzumab.
Patients treated with Kadcyla have higher rates of nausea (35%) than with trastuzumab alone.
No provided label excerpts provide nausea incidence values (including 35%) or comparison to trastuzumab.
Patients treated with Kadcyla have higher rates of anemia (25%) than with trastuzumab alone.
No provided label excerpts provide anemia incidence values (including 25%) or comparison to trastuzumab.
Kadcyla was approved by the FDA in December 2019 for early breast cancer based on KATHERINE data.
No provided label excerpts include FDA approval date.
Kadcyla received EU approval in 2020.
No provided label excerpts include EU approval date.
Ongoing trials are exploring combinations involving Kadcyla with tucatinib or endocrine therapy.
No provided label excerpts discuss ongoing trial combinations with tucatinib or endocrine therapy.
Contradictions
Low
AI Statement
Kadcyla adds toxicity including peripheral neuropathy at a rate of 10%.
Label Reference
Label 5.8 reports peripheral neuropathy overall incidence of 21% (EMILIA) and 32% (KATHERINE overall), not 10%.
Low
AI Statement
Kadcyla adds toxicity including liver enzyme elevation at a rate of 20%.
Label Reference
Label 5.1 describes hepatotoxicity/monitoring but does not provide an incidence of “20%” for liver enzyme elevation.
Important Omissions
Indication-specific details (e.g., exact labeled population criteria) are not verifiable because Section 1 (Indications and Usage) text is not provided in the prompt.
Importance:
Moderate
Contraindications and boxed warnings are not assessed because corresponding label text is not provided.
Importance:
Moderate
Adverse reaction rate claims for fatigue/nausea/anemia and efficacy outcome claims (event-free survival, hazard ratios, 4-year outcomes) cannot be validated because Section 14 and Adverse Reactions numeric tables are not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several safety-related monitoring elements (LVEF monitoring; thrombocytopenia/peripheral neuropathy qualitative incidence framing) are supported, but many other adverse reaction percentage claims and major efficacy/indication details are not verifiable against the provided label excerpts. Missing contraindications/boxed warning/pregnancy sections further limits safety alignment confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Most efficacy trial outcome claims, labeled indication wording, dosing regimen details, and multiple numeric adverse reaction rates are absent or not supported by the provided label excerpts (notably Section 1 and Section 14).
Suggested Improvement
Restrict claims to label-supported statements from the provided sections (e.g., 5.1, 5.2, 5.7, 5.8) and avoid asserting specific numeric rates (fatigue/nausea/anemia/liver enzyme elevation/peripheral neuropathy=10%) or efficacy outcomes (88.3%/77.0%, hazard ratio=0.50, 50% risk reduction) unless the corresponding Section 14 and Adverse Reactions numeric tables are included.